Skip to main content

Table 3 Diagnostic performance of biomarker panels in extracellular vesicles for pancreatic cancer

From: Extracellular vesicle biomarkers for pancreatic cancer diagnosis: a systematic review and meta-analysis

Study

Country

study design

Cases vs Controls

Specimen

Stage

Controls Status

Detection Method

Panel

SEN%

SPE%

AUC

P Value

   

Number

Age

Male (%)

         

Madhavan, 2015 [43]

Germany

Case–control

75/45

/

/

Serum

I-IV

NCb

qPCR

panel A

81

93

0.94

/

Flow cytometry

panel B

96

100

0.99

/

qPCR/Flow cytometry

panel A/B

100

93

/

/

Yang, 2017 [47]a

USA

prospective

22/21

/

/

plasma

/

NCb

NPS chip

panel C

86

86

/

/

panel D

82

90

/

/

panel E

86

81

/

/

panel F

95

81

/

/

Lewis, 2018 [50]

USA

Case–control

20/11

64/NA

/

Plasma

IIA- IIB

HC

ACE Immunoassay

panel G

94

91

0.99

/

20/6

64/60

70/33

Plasma

II A- II B

BPD

ACE Immunoassay

 

81

78

0.81

/

Xiao, 2019 [79]

China

Case–control

24/26

59/45

42/85

Plasma

/

HC

Flow cytometry

panel H

76e

96e

0.90

/

24/6

59/73

42/83

Plasma

/

CP

Flow cytometry

 

100e

66e

0.90

/

Yu, 2019 [85]a

China

Case–control

95/83

61/NA

57/66

Plasma

I-IV

NCc

ExLR-seq

panel I

94

92

0.94

/

52/83

/

/

I-II

 

88

92

0.91

/

35/83

/

/

I

 

85

92

0.90

/

17/83

/

/

II

 

94

92

0.93

/

43/83

/

/

III-IV

 

100

92

0.97

/

95/40

61/53

57/70

Plasma

I-IV

CP

ExLR-seq

 

94

90

0.95

/

52/40

/

/

I-II

 

89

90

0.92

/

35/40

/

/

I

 

86

90

0.91

/

17/40

/

/

II

 

94

90

0.95

/

43/40

/

/

III-IV

 

100

90

0.99

/

95/43

61/63

57/62

Plasma

I-IV

HC

ExLR-seq

 

94

93

0.92

/

Rodrigues, 2019 [33]a

USA

Case–control

20/12

/

45/25

serum

 

NCf

nanoparticle-and dyebased fluorescent immunoassay

panel Q

/

/

0.95

/

Reese, 2020 [31]

Germany

Case–control

56/33

/

64/52

Serum-EpCAM

II-IV

NCc

qPCR

panel J

64e

91e

0.84

0.0004

Zhou, 2020 [62]

China

Case–control

30/10

60/58

/

Plasma

I-IV

NCd

3D mircrofluidic chip

panel K

100e

100e

1.00

/

Wu, 2020 [61]

China

Case–control

30/10

62/51

60/80

serum

0-IV

CP

qPCR

panel L

93

80

/

/

Pu, 2020 [25]

China

Case–control

36/65

/

/

Plasma

I-IV

HC

cationic lipoplex nanoparticle

panel M

75 e

80 e

0.79

 < 0.0001

Qin, 2021 [63]a

China

Case–control

44/27

/

50/44

Plasma

I-IV

HC

qPCR

panel N

75e

74e

0.78

/

      

panel P

91e

74e

0.89

/

44/40

/

50/65

  

CP

panel N

92e

40e

0.71

/

      

panel P

64e

90e

0.77

/

44/67

 

50/57

  

NCc

panel N

72e

63e

0.70

/

      

panel P

53e

83e

0.72

/

Li, 2021 [76]a

China

Case–control

21/29

54/62

43/55

plasma

/

HC

AbMB-bioChol paltform

panel R

38e

93e

0.74

/

Wu, 2021 [71]

China

Case–control

284/117

/

59/62

plasma

I-IV

HC

ExLR-seq

panel S

80e

73e

0.86

/

284/100

/

59/46

  

CP

  

64e

82e

0.84

/

14/32

/

/

 

/

HC

RNA-seq

panel T

100

100

1.00

/

Verel-Y, 2021 [73]

Germany

Case–control

72/20

/

50/NA

Serum

I-IV

HC

bead-coupled FACS/qPCR

panel U

100

100

1.00

/

panel V

91e

82e

0.93

/

Kim, 2021 [77]a

Korea

Case–control

20/20

61/51

70/50

plasma

I-III

CL

qPCR

panel W

38e

95e

0.69

/

panel X

65e

99e

0.77

/

panel Y

76e

75e

0.84

/

panel Z

85e

81e

0.87

/

panel 1

56e

95e

0.79

/

panel 2

81

80

0.87

/

panel 3

76

90

0.87

/

panel 4

76

90

0.90

/

panel 5

81

85

0.86

/

panel 6

76

85

0.87

/

panel 7

76

85

0.91

/

panel 8

86

90

0.91

/

Kim, 2021 [77]a

Korea

Case–control

20/20

61/51

70/50

plasma

I-III

CL

qPCR

panel 9

76

90

0.93

/

panel 10

81

85

0.91

/

panel 11

67

90

0.81

/

panel 12

76

90

0.90

/

panel 13

86

90

0.94

/

panel 14

90

90

0.95

/

panel 15

86

90

0.94

/

panel 16

81

85

0.92

/

panel 17

86

90

0.91

/

panel 18

76

90

0.94

/

panel 19

90

85

0.94

/

panel 20

81

90

0.96

/

panel 21

86

90

0.94

/

panel 22

90

90

0.96

/

panel 23

90

85

0.95

/

panel 24

90

90

0.96

/

panel 25

86

90

0.95

/

panel 26

86

85

0.96

/

panel 27

90

90

0.97

/

Guo, 2021 [78]a

China

Case–control

27/15

57/43

63/60

plasma

IB-IV

CP

small RNA sequencing

panel 28

81

93

0.88

/

30/18

63/44

63/72

IB-III

 

panel 29

/

/

0.94

/

panel 30

/

/

0.94

/

panel 31

/

/

0.94

/

panel 32

/

/

0.94

/

panel 33

/

/

0.94

/

panel 34

/

/

0.94

/

Guo, 2021 [78]a

China

Case–control

30/18

63/44

63/72

plasma

IB-III

CP

small RNA sequencing

panel 35

/

/

0.93

/

panel 36

/

/

0.93

/

panel 37

/

/

0.93

/

panel 38

/

/

0.93

/

panel 39

/

/

0.93

/

panel 40

/

/

0.93

/

panel 41

/

/

0.92

/

panel 42

/

/

0.92

/

panel 43

/

/

0.92

/

panel 44

/

/

0.92

/

panel 45

/

/

0.92

/

panel 46

/

/

0.92

/

panel 47

/

/

0.92

/

panel 48

/

/

0.92

/

panel 49

/

/

0.91

/

panel 50

/

/

0.91

/

panel 51

/

/

0.91

/

panel 52

/

/

0.91

/

panel 53

/

/

0.91

/

panel 54

/

/

0.91

/

panel 55

/

/

0.91

/

panel 56

/

/

0.91

/

panel 57

/

/

0.91

/

panel 58

/

/

0.91

/

panel 59

/

/

0.90

/

panel 60

/

/

0.90

/

Guo, 2021 [78]a

China

Case–control

30/18

63/44

63/72

plasma

IB-III

CP

small RNA sequencing

panel 61

/

/

0.90

/

panel 62

/

/

0.90

/

panel 63

/

/

0.90

/

panel 64

/

/

0.90

/

panel 65

/

/

0.90

/

panel 66

/

/

0.90

/

panel 67

/

/

0.90

/

panel 68

/

/

0.90

/

panel 69

/

/

090

/

panel 70

/

/

0.90

/

panel 71

/

/

0.90

/

panel 72

/

/

0.90

/

panel 73

/

/

0.90

/

panel 74

/

/

0.90

/

panel 75

/

/

0.90

/

panel 76

/

/

0.89

/

panel 77

/

/

0.89

/

panel 78

/

/

0.89

/

panel 79

/

/

0.89

/

panel 80

/

/

0.89

/

panel 81

/

/

0.89

/

panel 82

/

/

0.89

/

panel 83

/

/

0.89

/

panel 84

/

/

0.89

/

panel 85

/

/

0.89

/

panel 86

/

/

0.89

/

Guo, 2021 [78]a

China

Case–control

30/18

63/44

63/72

plasma

IB-III

CP

small RNA sequencing

panel 87

/

/

0.89

/

panel 88

/

/

0.89

/

panel 89

/

/

0.89

/

panel 90

/

/

0.88

/

panel 91

/

/

0.88

/

panel 92

/

/

0.88

/

panel 93

/

/

0.88

/

panel 94

/

/

0.88

/

panel 95

/

/

0.88

/

panel 96

/

/

0.88

/

panel 97

/

/

0.88

/

panel 98

/

/

0.88

/

panel 99

/

/

0.88

/

panel 100

/

/

0.88

/

panel 101

/

/

0.88

/

panel 102

/

/

0.88

/

panel 103

/

/

0.87

/

panel 104

/

/

0.87

/

panel 105

/

/

0.87

/

panel 106

/

/

0.87

/

panel 107

/

/

0.87

/

panel 108

/

/

0.87

/

panel 109

/

/

0.87

/

panel 110

/

/

0.86

/

panel 111

/

/

0.86

/

panel 112

/

/

0.86

/

Guo, 2021 [78]a

China

Case–control

30/18

63/44

63/72

plasma

IB-III

CP

small RNA sequencing

panel 113

/

/

0.86

/

panel 114

/

/

0.86

/

panel 115

/

/

0.85

/

panel 116

/

/

0.85

/

panel 117

/

/

0.85

/

panel 118

/

/

0.84

/

panel 119

/

/

0.83

/

panel 120

/

/

0.83

/

panel 121

/

/

0.83

/

panel 122

/

/

0.83

/

panel 123

/

/

0.83

/

panel 124

/

/

0.82

/

panel 125

/

/

0.82

/

panel 126

/

/

0.822

/

panel 127

/

/

0.82

/

panel 128

/

/

0.82

/

panel 129

/

/

0.81

/

panel 130

/

/

0.81

/

panel 131

/

/

0.80

/

panel 132

/

/

0.79

/

panel 133

/

/

0.77

/

panel 134

/

/

0.76

/

panel 135

/

/

0.76

/

panel 136

/

/

0.76

/

panel 137

/

/

0.75

/

panel 138

/

/

0.74

/

Guo, 2021 [78]a

China

Case–control

30/18

63/44

63/72

plasma

IB-III

CP

small RNA sequencing

panel 139

/

/

0.74

/

panel 140

/

/

0.74

/

panel 141

/

/

0.72

/

panel 142

/

/

0.72

/

panel 143

/

/

0.72

/

panel 144

/

/

0.71

/

panel 145

/

/

0.71

/

panel 146

/

/

0.71

/

  1. SENs, SPEs and AUCs in bold fonts represent results from validation set (non-bold fonts represent results without validation)
  2. AUC area under the curve, ACE alternating current electrokinetic, AbMB antibody-conjugated magnetic beads, BPD benign pancreatic disease, CP chronic pancreatitis, CL cholecytitis, HC healthy control, FACS Cartoon of protocol for flow cytometry, NC noncancerous, NPS nanoplasmonic sensor, SEN sensitivity, SPE specificity
  3. arepresent markers extracted from extracellular vesicles
  4. bHC, CP, and benign pancreatic tumor
  5. cHC and CP
  6. dno history of cancer
  7. erepresent 估算值
  8. frepresent liver injury, pancreatitis, and cholangitis
  9. Panel A: miR-1246, miR-4644, miR-3976, miR-4306; Panel B, CD44v6/Tspan8/EpCAM/CD104; panel C, EGFR/EPCAM/HER2/MUC1; Panel D, EGFR/EPCAM/GPC1/WNT2; Panel E, EGFR/EPCAM/MUC1/GPC1/WNT2; Panel F, EGFR/EPCAM/HER2/MUC1/GPC1/WNT2; Panel G, GPC1/CD63; Panel H, GPC1/CD82; Panel I, FGA/KRT19/HIST1H2BK/ITIH2/MARCH2/CLDN1/MAL2/TIMP1; panel Q, EpCAM/EphA2; Panel J, miR-200c/miR-200b; Panel K, miR-451a/21/10b/EphA2; Panel L, miR-21/210; Panel M, miR-21/10b; Panel N, FBXO7/MORF4L1//DDX17/TALDO1//AHNAK/TUBA1B; Panel P, FBXO7/MORF4L1//DDX17/TALDO1//AHNAK/TUBA1B//CD44/SETD3; panel R, EGFR/EpCAM/GPC1/EphA2; panel S, HIST2H2AA3/LUZP6/HLA-DRA; panel T, HIST2H2AA3/HIST1H4K/HLD-DRA/RN7SL1/LUZP6/FAM184B/FGF23/NEUROD2/miR663AHG/GPM6A; panel U, ADAM8/miR-720; panel V, ADAM8/miR-451; panel W, ITGA2/ITGAV/GPC1/miR-10b; panel X, ITGA2/ITGAV/GPC1/miR-21; panel Y, ITGA2/ITGAV/GPC1/miR-155; panel Z, ITGA2/ITGAV/GPC1/miR-429; panel 1, ITGA2/ITGAV/GPC1/miR-1290; panel 2, ITGA2/ITGAV/GPC1/miR-21/miR-155; panel 3, ITGA2/ITGAV/GPC1/miR-21/miR-429; panel 4, ITGA2/ITGAV/GPC1/miR-21/miR-1290; panel 5, ITGA2/ITGAV/GPC1/miR-21/miR-10b; panel 6, ITGA2/ITGAV/GPC1/miR-155/miR-429; panel 7, ITGA2/ITGAV/GPC1/miR-155/miR-1290; panel 8, ITGA2/ITGAV/GPC1/miR-155/miR10b; panel 9, ITGA2/ITGAV/GPC1/miR-429/miR-1290; panel 10, ITGA2/ITGAV/GPC1/miR-429/miR-10b; panel 11, ITGA2/ITGAV/GPC1/miR-1290/miR-10b; panel 12, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-429; panel 13, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-10b; panel 14, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-1290; panel 15, ITGA2/ITGAV/GPC1/miR-21/miR-429/miR-1290; panel 16, ITGA2/ITGAV/GPC1/miR-21/miR-429/miR-10b; panel 17, ITGA2/ITGAV/GPC1/miR-21/miR-1290/miR-10b; panel 18, ITGA2/ITGAV/GPC1/miR-155/miR-429/miR-1290; panel 19, ITGA2/ITGAV/GPC1/miR-155/miR-429/miR-10b; panel 20, ITGA2/ITGAV/GPC1/miR-155/miR-1290/miR-10b; panel 21, ITGA2/ITGAV/GPC1/miR-429/miR-1290/miR-10b; panel 22, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-429/miR-1290; panel 23, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-429/miR-10b; panel 24, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-1290/miR-10b; panel 25, ITGA2/ITGAV/GPC1/miR-21/miR-429/miR-1290/miR-10b; panel 26, ITGA2/ITGAV/GPC1/miR-155/miR-429/miR-1290/miR-10b; panel 27, ITGA2/ITGAV/GPC1/miR-21/miR-155/miR-429/miR-1290/miR-10b; panel 28, miR-95-3p/miR-26b-5p; panel 29, miR-95-3p/miR-3605-3p; panel 30, miR-95-3p/miR-128-3p; panel 31, miR-95-3p/miR-30d-5p; panel 32,miR-95-3p/miR-505-5p; panel 33,miR-95-3p/miR-148b-3p; panel 34, miR-95-3p/miR-342-5p; panel 35,miR-95-3p/miR-532-5p; panel 36, miR-95-3p/let-7 g-5p; panel 37, miR-95-3p/miR-151a-3p; panel 38, miR-95-3p/miR-181a-2-3p; panel 39,miR-95-3p/miR-550a-5p; panel 40, miR-95-3p/let-7b-5p; panel 41, miR-95-3p/miR-191-5p; panel 42,miR-95-3p/miR-92a-3p; panel 43, miR-95-3p/miR-941; panel 44, miR-95-3p/miR-106b-3p; panel 45, miR-95-3p/miR-7706; panel 46, miR-95-3p/miR-183-5p; panel 47,miR-95-3p/miR-25-5p; panel 48,miR-95-3p/miR-486-3p; panel 49,miR-95-3p/miR-3158-3p; panel 50, miR-95-3p/miR-7-5p; panel 51, miR-95-3p/miR-101-3p; panel 52,miR-95-3p/miR-210-3p; panel 53,miR-95-3p/miR-550a-3-5p; panel 54, miR-95-3p/miR-584-5p; panel 55,miR-95-3p/miR-140-3p; panel 56, miR-95-3p/miR-4732-5p; panel 57, miR-95-3p/miR-363-5p; panel 58,miR-95-3p/miR-4326; panel 59, miR-95-3p/miR-1294; panel 60,miR-95-3p/miR-486-5p; panel 61, miR-95-3p/miR-185-3p; panel 62,miR-95-3p/miR-4732-3p; panel 63, miR-95-3p/miR-92b-3p; panel 64,miR-95-3p/miR-423-5p; panel 65,miR-95-3p/miR-503-5p; panel 66, miR-95-3p/miR-1180-3p; panel 67, miR-95-3p/miR-25-3p; panel 68,miR-95-3p/miR-92b-5p; panel 69, miR-95-3p/miR-1284; panel 70,miR-95-3p/miR-17-5p; panel 71, miR-95-3p/miR-2110; panel 72, miR-95-3p/miR-24–2-5p; panel 73,miR-95-3p/miR-339-3p; panel 74,miR-95-3p/miR-660-5p; panel 75,miR-95-3p/miR-6842-3p; panel 76, miR-95-3p/let-7d-5p; panel 77, miR-95-3p/miR-30e-5p; panel 78, miR-95-3p/miR-628-3p; panel 79, miR-95-3p/miR-629-5p; panel 80, miR-95-3p/let-7i-5p; panel 81, miR-95-3p/miR-142-5p; panel 82,miR-95-3p/miR-182-5p; panel 83, miR-95-3p/miR-1908-5p; panel 84, miR-95-3p/miR-425-5p; panel 85,miR-95-3p/miR-942-5p; panel 86, miR-95-3p/miR-93-5p; panel 87, miR-95-3p/miR-363-3p; panel 88, miR-95-3p/miR-18a-3p; panel 89, miR-95-3p/miR-320a; panel 90, miR-95-3p/miR-421; panel 91, miR-95-3p/miR-501-3p; panel 92,miR-95-3p/let-7a-3p; panel 93, miR-95-3p/miR-16–2-3p; panel 94, miR-95-3p/miR-16-5p; panel 95,miR-95-3p/miR-130b-3p; panel 96, miR-95-3p/miR-3613-5p; panel 97, miR-95-3p/miR-451a; panel 98, miR-95-3p/miR-20b-5p; panel 99, miR-95-3p/miR-103a-3p; panel 100, miR-95-3p/miR-1224-5p; panel 101, miR-95-3p/miR-185-5p; panel 102, miR-95-3p/miR-20a-5p; panel 103, miR-95-3p/miR-186-5p; panel 104, miR-95-3p/miR-3615; panel 105, miR-95-3p/miR-7976; panel 106, miR-95-3p/miR-652-3p; panel 107, miR-95-3p/miR-107; panel 108, miR-95-3p/miR-181a-5p; panel 109, miR-95-3p/miR-15b-3p; panel 110, miR-95-3p/let-7b-3p; panel 111, miR-95-3p/miR-10b-5p; panel 112, miR-95-3p/miR-24-3p; panel 113, miR-95-3p/miR-106b-5p; panel 114, miR-95-3p/miR-15a-5p; panel 115, miR-95-3p/miR-197-3p; panel 116, miR-95-3p/miR-32-5p; panel 117, miR-95-3p/miR-450b-5p; panel 118, miR-95-3p/let-7e-5p; panel 119, miR-95-3p/miR-155-5p; panel 120, miR-95-3p/miR-361-5p; panel 121, miR-95-3p/miR-126-3p; panel 122, miR-95-3p/miR-484; panel 123, miR-95-3p/miR-30a-5p; panel 124, miR-95-3p/miR-27a-3p; panel 125, miR-95-3p/miR-29a-3p; panel 126, miR-95-3p/miR-335-5p; panel 127, miR-95-3p/miR-125a-5p; panel 128, miR-95-3p/miR-338-5p; panel 129, miR-95-3p/miR-139-5p; panel 130, miR-95-3p/miR-22-5p; panel 131, miR-95-3p/miR-23a-3p; panel 132, miR-95-3p/miR-382-5p; panel 133, miR-95-3p/miR-543; panel 134, miR-95-3p/miR-499a-5p; panel 135, miR-95-3p/miR-4433b-3p; panel 136, miR-95-3p/miR-1228-5p; panel 137, miR-95-3p/miR-99b-5p; panel 138, miR-95-3p/miR-143-3p; panel 139, miR-95-3p/miR-206; panel 140, miR-95-3p/miR-224-5p; panel 141, miR-95-3p/miR-10a-5p; panel 142, miR-95-3p/miR-223-3p; panel 143, miR-95-3p/miR-134-5p; panel 144, miR-95-3p/miR-485-5p; panel 145, miR-95-3p/miR-760; panel 146, miR-95-3p/miR-199b-3p
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us